Tyrosine kinase inhibitorPhase 3 trialInvestigational
Tucatinib
How it works
Blocks the HER2 receptor on cancer cells, preventing growth signals and inhibiting cell division.
Cancer types
Colorectal Cancer— HER2-positive
Breast Cancer— HER2-positive
Efficacy
Studies show that tucatinib, when combined with trastuzumab and capecitabine, can improve progression-free survival in HER2-positive patients.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing New Treatment for HER2-Positive Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Testing a Combination Treatment for HER2 Positive Breast Cancer | Breast Cancer | phase-1 | — | Source → |
| Study of Tucatinib and Trastuzumab-Pertuzumab for Metastatic HER2+ Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Testing Disitamab Vedotin with Tucatinib in Advanced Solid Tumors | Breast Cancer | phase-2 | — | Source → |
| New Imaging Technique Helps Track Effectiveness of Cancer Treatment | Breast Cancer | animal-study | Tucatinib significantly decreases intratumoral proliferation and hypoxia in both cell-line and patient-derived xenograft models of HER2+ breast cancer. | Source → |
| Tucatinib Efficacy in Danish HER2-Positive Breast Cancer Patients | Breast Cancer | observational | Median progression-free survival was 8.7 months and median overall survival was 22.4 months. | Source → |
| Combining Tucatinib and Radiation for HER2 Positive Breast Cancer Brain Metastases | Breast Cancer | phase-2 | Local brain control was 94% at 12-months and 81% at 24-months. | Source → |
| New Treatments for HER2-Positive Breast Cancer | Breast Cancer | review | — | Source → |
| Tucatinib Shows Promise for HER2-Positive Breast Cancer | Breast Cancer | meta-analysis | — | Source → |
| Tucatinib Preserves Quality of Life in Breast Cancer Patients | Breast Cancer | phase-3 | The risk of meaningful deterioration on EQ-VAS was reduced 19% in the tucatinib vs. placebo arm. | Source → |
| Tucatinib May Improve Leukemia Treatment by Targeting Drug-Resistant Cells | Leukemia | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.